Cover Image
市場調查報告書

全球細胞療法市場、臨床實驗平台預測

Global Cell Therapy Market & Clinical Pipeline Outlook 2022

出版商 KuicK Research 商品編碼 302594
出版日期 內容資訊 英文 850 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球細胞療法市場、臨床實驗平台預測 Global Cell Therapy Market & Clinical Pipeline Outlook 2022
出版日期: 2016年11月03日 內容資訊: 英文 850 Pages
簡介

本報告提供全球細胞療法市場相關調查分析,市場概要,應用,機制,臨床實驗平台,上市產品,競爭情形等相關的系統性資訊。

第1章 細胞療法概要

第2章 細胞療法的治療的必要性

  • 幹細胞研究的崛起
  • 使用研究、治療用的幹細胞的優點

第3章 細胞療法的幹細胞的應用

  • 幹細胞能力差異化
  • 幹細胞的來歷

第4章 細胞療法的應用:各治療領域

  • 循環系統疾病的細胞療法
  • 神經疾病的細胞療法
  • 發炎性疾病的細胞療法
  • 糖尿病的細胞療法
  • 癌症的細胞療法
  • 癌症的幹細胞療法

第5章 細胞療法的機制

  • 幹細胞療法的2大機制的原理
  • 老年癡呆症的作用機制

第6章 細胞療法的通知方法

  • 通知方法概要
  • 直接
  • 間接

第7章 細胞療法的治療的機制

  • 同類幹細胞治療
  • 自我幹細胞治療

第8章 全球細胞療法市場概要

  • 目前市場方案
  • 細胞療法的全球市場的目前趨勢
  • 全球細胞療法的臨床實驗平台概要

第9章 全球細胞療法市場:各地區

  • 北美
  • 歐洲
  • 亞洲
  • 其他

第10章 全球細胞療法市場動態

  • 有利的市場參數
  • 阻礙市場成長要素

第11章 全球細胞療法市場未來發展預測

第12章 全球細胞療法的臨床實驗平台:各企業,各適應症,各相位

  • 階段不明
  • 研究
  • 前臨床
  • 臨床
  • 第0相
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第二/三階段
  • 第三階段
  • 申請完畢
  • 已通過核准

第13章 已上市的細胞療法臨床分析:各企業,各適應症

第14章 競爭情形

  • AlloCure
  • Arteriocyte Medical Systems
  • Athersys Inc.
  • Baxter Healthcare Corporation
  • Bone Therapeutics
  • Celgene Corporation
  • Cell Medica
  • Cellerant Therapeutics
  • FibrocellScinence
  • Forticell Bioscience
  • Genzyme Corporation
  • Green Cross Cell
  • Histogenics Corporation
  • InnovacellBiotechnologie AG
  • Intrexon Corporation
  • Intercytex
  • ISTO Technologies
  • Macrocure
  • Mesoblast
  • Molmed
  • Nuo Therapeutics Inc
  • OmniCyte
  • Opexa Therapeutics
  • Organogenesis
  • Pharmicell
  • TCA Cellular Therapy
  • Stem Cell Inc.
  • Teva Pharmaceuticals
  • Tigenix
  • Vericel Corporation

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

“Global Cell Therapy Market & Clinical Pipeline Outlook 2022” report published by Kuick Research gives comprehensive insight on the ongoing clinical and nonclinical trends in the global cell therapy market. Report analyzes the need and the application of cell therapy in multiple therapeutic areas along with the mechanism and delivery methods for cell therapy based treatment. The parameters impacting the growth of the market and the corresponding challenges limiting the commercialization of cell therapies are explained in the report.

The idea of cell therapy was in pharmaceutical industry for several decades but significant development was not made due to technological challenges. In recent years, cell therapy has gained widespread acceptance among physicians and patients due to its ability to treat various diseases. Several decades of research and development has allowed the investigators to come forth with solutions which can't be provided by conventional therapeutics. Theoretically, it could be used to cure plethora of diseases but underdeveloped technology has limited its usage to limited indications.

Several indications have been found to be curable with the help of cell therapies and indications are expected to be increased in near future. Cerebral disorders like Parkinson's disease and Alzheimer's disease are under investigation for treatment with the help of cell therapies. They are also being investigated for cardiovascular disease in which their aim is to restore normal heart functions. Investigators are also trying to find their safety and efficacy in treating various malignancies. On-going research is also aimed at curing metabolic disorder like diabetes mellitus type 1 in which patients tends to lack insulin production. Investigators are trying to restore the function of liver and kidney by supplementing them with modified cell of respective origins. Several clinical trials have been instigated across the globe in which their efficacy against different disease is being studies.

Cell therapy has potential in tissue development and regenerative medicine that could be used to make functional body parts. However, such researches are limited to laboratory levels and it will take very long time before successful instigation of clinical trials. Chances of their success are high as they have been able to develop the basic frame work in which conditions for growing different cells have been standardized. Now focus is on development of biocompatible matrix over which these cells could grow in predefined shape. Some materials have been found that are degraded from the system leaving behind the layer of cells in that shape. This shows that their approach is workable and someday they may be able to develop fully functional human organs.

Different individuals may respond to these therapies in different way and some of them develop hypertensive reaction during course of treatment. Some skeptics have raised concerns about safety of such treatment because more underlying principles have yet to be deciphered. For efficient treatment it is necessary to maintain their viability for elongated time and investigators are trying to figure out such methods. Cell therapy has significant commercialization potential but lots of work has yet to be done because its long-term effect on body is not known.

“Global Cell Therapy Market & Clinical Pipeline Outlook 2022” Highlights:

  • Introduction & Classification of Cell Therapies
  • Mechanism of Cell Therapy
  • Global Cell Therapy Market Analysis
  • Role of Stem Cells in Cell Therapy
  • Global Cell Therapy Clinical Pipeline by Country, Indication & Phase
  • Global Cell Therapy Clinical Pipeline: 476
  • Marketed Cell Therapies: 20

Table of Contents

1. Introduction to Cell Therapy

2. Necessity for Cell Therapy Treatment

  • 2.1. Emergence of Stem Cell Research
  • 2.2. Benefits of Using the Stem Cell for Research & Treatment

3. Application of Stem Cells in Cell Therapy

  • 3.1. Stem Cells Ability to Differentiate
    • 3.1.1. Totipotent Stem Cells
    • 3.1.2. Pluripotent Stem Cells
    • 3.1.3. Multipotent Stem Cells
    • 3.1.4. Unipotent Stem Cells
  • 3.2. Origin of Stem Cells
    • 3.2.1. Embryonic Stem Cells
    • 3.2.2. Adult Stem Cells
    • 3.2.3. Induced Pluripotent Stem Cells (iPSCs)

4. Applications of Cell Therapy by Therapeutic Area

  • 4.1. Cell Therapy for Cardiovascular Diseases
  • 4.2. Cell Therapy for Neurological Disorders
  • 4.3. Cell Therapy for Inflammatory Diseases
  • 4.4. Cell Therapy for Diabetes
  • 4.5. Cell Therapy for Cancer
  • 4.6. Cancer Stem Cells Therapy
    • 4.6.1. Therapies of Targeting the Cancer Stem Cells
      • 4.6.1.1. Targeting the Surface Markers
      • 4.6.1.2. Targeting the Signal Cascades
      • 4.6.1.3. Targeting the Microenvironment

5. Mechanism of Cell Therapy

  • 5.1. Two Major Mechanism Principles of Stem Cell Based Therapy
    • 5.1.1. Interaction of Modified Cells with Body
      • 5.1.1.1. Stem Cell Paracrine Actions in Heart Repair
    • 5.1.2. Mechanism of Regenerative Cell Therapy
      • 5.1.2.1. Regenerative Medicine Therapies for Diabetes
  • 5.2. Mechanism of Action in Alzheimer's Diseases

6. Delivery Method of Cell Based Therapy

  • 6.1. Outline to Delivery Methods
  • 6.2. Direct Delivery Methods
    • 6.2.1. Intravascular Infusions
    • 6.2.2. Trans- Mucosal Delivery
  • 6.3. Indirect Delivery of the Cells by Using the Carrier
    • 6.3.1. Natural Biomaterials
    • 6.3.2. Synthetic Biomaterials

7. Mechanism of Cell Therapy Treatment

  • 7.1. Allogeneic Stem Cell Therapy
  • 7.2. Autologous Stem Cell Therapy

8. Global Cell Therapy Market Overview

  • 8.1. Current Market Scenario
  • 8.2. Current Trends of Cell Therapy in Global Market
  • 8.3. Global Cell Therapies Clinical Pipeline Overview

9. Global Cell Therapy Market by Region

  • 9.1. North America
  • 9.2. Europe
  • 9.3. Asia
  • 9.4. Rest of the World

10. Global Cell Therapy Market Dynamics

  • 10.1. Favorable Market Parameters
  • 10.2. Factors Limiting Market Growth

11. Global Cell Therapy Market Future Prospect

12. Global Cell Therapies Clinical Pipeline by Company, Indication & Phase

  • 12.1. Unknown
  • 12.2. Research
  • 12.3. Preclinical
  • 12.4. Clinical
  • 12.5. Phase-0
  • 12.6. Phase-I
  • 12.7. Phase-I/II
  • 12.8. Phase-II
  • 12.9. Phase-II/III
  • 12.10. Phase-III
  • 12.11. Preregistration
  • 12.12. Registered

13. Marketed Cell Therapies Clinical Insight by Company & Indication

  • 13.1. T-Lymphocyte Cell Therapy (Immuncell-LC)
  • 13.2. Muscle-Derived Autologous Stem Cell Therapy (MyoCell & MyoCell SDF-1)
  • 13.3. Azficel-T (Laviv)
  • 13.4. Sipuleucel-T (Provenge)
  • 13.5. Placental Derived Mesenchymal Stem Cell Therapy - Osiris Therapeutics
  • 13.6. Remestemcel-L (Prochymal & TEMCELL HS Inj.)
  • 13.7. Autologous Mesenchymal Stem Cell Therapy - Pharmicell
  • 13.8. Autologous Cultured Chondrocytes (MACI)
  • 13.9. Mesenchymal Stem Cell Therapy for Cartilage Repair (Cartistem)
  • 13.10. Leukocyte Cell Therapy (CureXcell)
  • 13.11. Adipose Stem Cell Therapy (Adipocell (Anterogen), Cupistem & Queencell)
  • 13.12. Allogeneic Cultured Keratinocytes and Fibroblasts (Gintuit)
  • 13.13. Autologous Cultured Chondrocyte Implant (Carticel)
  • 13.14. Autologous Cultured Chondrocytes (CHONDRON)
  • 13.15. Autologous Chondrocytes (BioCart & BioCartII)
  • 13.16. Amniotic Cell Therapy (NuCel)
  • 13.17. Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical
  • 13.18. Autologous Cultured Chondrocytes (Chondrotransplant DISC)
  • 13.19. Autologous Cultured Myoblasts and Fibroblasts (Urocell)
  • 13.20. Human Skin Replacement (CellSpray & CellSpray XP)

14. Competitive Landscape

  • 14.1. AlloCure
  • 14.2. Arteriocyte Medical Systems
  • 14.3. Athersys Inc.
  • 14.4. Baxter Healthcare Corporation
  • 14.5. Bone Therapeutics
  • 14.6. Celgene Corporation
  • 14.7. Cell Medica
  • 14.8. Cellerant Therapeutics
  • 14.9. FibrocellScinence
  • 14.10. Forticell Bioscience
  • 14.11. Genzyme Corporation
  • 14.12. Green Cross Cell
  • 14.13. Histogenics Corporation
  • 14.14. InnovacellBiotechnologie AG
  • 14.15. Intrexon Corporation
  • 14.16. Intercytex
  • 14.17. ISTO Technologies
  • 14.18. Macrocure
  • 14.19. Mesoblast
  • 14.20. Molmed
  • 14.21. Nuo Therapeutics Inc
  • 14.22. OmniCyte
  • 14.23. Opexa Therapeutics
  • 14.24. Organogenesis
  • 14.25. Pharmicell
  • 14.26. TCA Cellular Therapy
  • 14.27. Stem Cell Inc.
  • 14.28. Teva Pharmaceuticals
  • 14.29. Tigenix
  • 14.30. Vericel Corporation

List of Figures

  • Figure 1-1: Properties of the Stem Cell
  • Figure 1-2: Outline to the Cell Therapy Components
  • Figure 2-1: History of Stem Cell Research
  • Figure 2-2: Promise of the Stem Cell Research
  • Figure 3-1: Type of Stem Cells on the Basis of Ability to Differentiate
  • Figure 3-2: Type of Stem Cells on the Basis of Origin
  • Figure 4-1: Stem Cell Therapy for Cardiovascular Diseases
  • Figure 4-2: Cell Therapy in Parkinson's disease
  • Figure 4-3: Cell Therapy for Inflammatory Disorder
  • Figure 4-4: Cell Therapy for Diabetes
  • Figure 4-5: Strategies which are adopted for targeting the Cancer Stem Cells
  • Figure 5-1: Mechanism of Paracrine Signaling
  • Figure 5-2: Demonstration of the Endocrine Signaling
  • Figure 5-3: Illustration of the Autocrine Signaling
  • Figure 5-4: Paracrine Signaling in Heart Repair
  • Figure 5-5: Treatment of Alzheimer's Diseases
  • Figure 7-1: Allogeneic Stem Cell Therapy
  • Figure 7-2: Steps of Autologous Stem Cell Therapy
  • Figure 8-1: Global Cell Therapy Market (US$ Billion), 2012-2022
  • Figure 8-2: Global - Cell Therapies Clinical Pipeline by Phase (%), 2016 till 2022
  • Figure 8-3: Global - Cell Therapies Clinical Pipeline by Phase (Numbers), 2016 till 2022
  • Figure 8-4: Global - Cell Therapies Clinical Pipeline by Phase (%), 2016 till 2022
  • Figure 8-5: Global - Cell Therapies Clinical Pipeline by Phase (Numbers), 2016 till 2022
  • Figure 10-1: Favorable Market Drivers
  • Figure 10-2: Factors Limiting the Cell Therapy Market
  • Figure 11-1: Future Projections of Stem Cell Therapy
  • Figure 14-1: Arteriocyte Medical Systems Clinical Pipeline
  • Figure 14-2: Bone Therapeutics Clinical Pipeline
  • Figure 14-3: Celgene Clinical Pipeline
  • Figure 14-4: Cellerant Therapeutics Clinical Pipeline
  • Figure 14-5: Fibrocell Science Clinical Pipeline
  • Figure 14-6: Genzyme Clinical Pipeline
  • Figure 14-7: Intrexon Clinical Pipeline
  • Figure 14-8: ISTO Clinical Pipeline
  • Figure 14-9: Mesoblast Clinical Pipeline
  • Figure 14-10: Molmed Clinical Pipeline
  • Figure 14-11: Pharmicell Clinical Pipeline
  • Figure 14-12: Tigenix Clinical Pipeline
  • Figure 14-13: Vericel Corporation Clinical Pipeline

List of Tables

  • Table 7-1: Difference between Embryonic, Adult & Induced Stem Cells
  • Table 8-1: List of the Blockbuster Drugs
  • Table 9-1: Cell Therapy Market Growth
Back to Top